Advanced

Trophic Factor Gene Therapy for Parkinson's Disease

Kordower, Jeffrey H. and Björklund, Anders LU (2013) In Movement Disorders 28(1). p.96-109
Abstract
Parkinson's disease (PD) is a chronic and progressive neurodegenerative movement disorder for which there is presently no cure. Pharmacological remedies targeting the dopaminergic network are relatively effective at ameliorating motor deficits, especially in the early stages of the disease, but none of these therapies are curative and many generate their own problems. Recent advances in PD research have demonstrated that gene delivery of trophic factors, glial cell line-derived neurotrophic factor (GDNF) and neurturin, in particular, can provide structural and functional recovery in rodent and nonhuman primate models of PD. Similar success has been gleaned in open-label clinical trials, although this has yet to be realized in... (More)
Parkinson's disease (PD) is a chronic and progressive neurodegenerative movement disorder for which there is presently no cure. Pharmacological remedies targeting the dopaminergic network are relatively effective at ameliorating motor deficits, especially in the early stages of the disease, but none of these therapies are curative and many generate their own problems. Recent advances in PD research have demonstrated that gene delivery of trophic factors, glial cell line-derived neurotrophic factor (GDNF) and neurturin, in particular, can provide structural and functional recovery in rodent and nonhuman primate models of PD. Similar success has been gleaned in open-label clinical trials, although this has yet to be realized in double-blinded analyses. This work reviews the field of trophic factor gene delivery for PD. (C) 2013 Movement Disorder Society (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Parkinson's disease, GDNF, neurturin, regeneration, neuroprotection
in
Movement Disorders
volume
28
issue
1
pages
96 - 109
publisher
John Wiley & Sons
external identifiers
  • wos:000314995300012
  • scopus:84873445906
ISSN
0885-3185
DOI
10.1002/mds.25344
language
English
LU publication?
yes
id
aa19885e-4170-46a0-80f2-c9942dc73c13 (old id 3589835)
date added to LUP
2013-04-02 07:46:21
date last changed
2019-04-07 03:02:54
@article{aa19885e-4170-46a0-80f2-c9942dc73c13,
  abstract     = {Parkinson's disease (PD) is a chronic and progressive neurodegenerative movement disorder for which there is presently no cure. Pharmacological remedies targeting the dopaminergic network are relatively effective at ameliorating motor deficits, especially in the early stages of the disease, but none of these therapies are curative and many generate their own problems. Recent advances in PD research have demonstrated that gene delivery of trophic factors, glial cell line-derived neurotrophic factor (GDNF) and neurturin, in particular, can provide structural and functional recovery in rodent and nonhuman primate models of PD. Similar success has been gleaned in open-label clinical trials, although this has yet to be realized in double-blinded analyses. This work reviews the field of trophic factor gene delivery for PD. (C) 2013 Movement Disorder Society},
  author       = {Kordower, Jeffrey H. and Björklund, Anders},
  issn         = {0885-3185},
  keyword      = {Parkinson's disease,GDNF,neurturin,regeneration,neuroprotection},
  language     = {eng},
  number       = {1},
  pages        = {96--109},
  publisher    = {John Wiley & Sons},
  series       = {Movement Disorders},
  title        = {Trophic Factor Gene Therapy for Parkinson's Disease},
  url          = {http://dx.doi.org/10.1002/mds.25344},
  volume       = {28},
  year         = {2013},
}